Company Overview
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer. The company is headquartered in Jerusalem, Israel.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.34.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +333.92% |
| 6 Months: | +121.16% |
| 3 Months: | +59.91% |
| 1 Month: | +12.94% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)59.86 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | DRTS Alpha Tau Medical Ltd. PHARMA | 14.84 | -14.27 | $1.37B | 0.00% | -44.45% | -141.68% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | 9.31M | 9.65M | 10.73M | 12.60M | 13.31M |
| Operating Income | -9.31M | -9.65M | -10.73M | -12.60M | -13.31M |
| EBITDA | -9.31M | -9.18M | -11.20M | -12.47M | -13.31M |
| Interest Expense | - | - | - | - | - |
| Pretax Income | -8.59M | -10.05M | -11.69M | -12.17M | -22.95M |
| Tax Provision | 99.00K | 65.00K | -8.00K | -35.00K | -11.00K |
| Net Income | -8.69M | -10.11M | -11.69M | -12.14M | -22.94M |
| Diluted EPS | -0.12 | - | - | - | -0.26 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 32.14M | 35.68M | 36.04M | 42.29M |
| Operating Income | - | -32.14M | -35.68M | -36.04M | -42.29M |
| EBITDA | - | -32.76M | -27.99M | -30.34M | -40.93M |
| Interest Expense | - | 0 | 75.00K | 303.00K | 347.00K |
| Pretax Income | - | -33.74M | -29.14M | -31.74M | -42.51M |
| Tax Provision | - | 20.00K | 16.00K | 6.00K | 121.00K |
| Net Income | - | -33.76M | -29.16M | -31.75M | -42.63M |
| Diluted EPS | - | -0.53 | -0.42 | -0.45 | -0.53 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 120.15M | 107.39M | 86.20M | 105.65M |
| Current Assets | - | 106.48M | 85.76M | 64.23M | 78.30M |
| Cash & Equivalents | - | 5.84M | 12.66M | 13.72M | 12.20M |
| Inventory | - | - | - | - | - |
| Receivables | - | 313.00K | 344.00K | 332.00K | 336.00K |
| Total Liabilities | - | 14.49M | 22.91M | 23.54M | 28.55M |
| Current Liabilities | - | 4.34M | 7.10M | 8.68M | 10.51M |
| Long Term Debt | - | - | 5.61M | 5.56M | 6.35M |
| Total Debt | - | 5.19M | 13.28M | 12.54M | 13.73M |
| Total Equity | - | 105.66M | 84.47M | 62.67M | 77.10M |
| Shares Outstanding | - | 69.11M | 69.67M | 70.38M | 88.01M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -23.88M | -17.96M | -19.78M | -26.68M |
| Investing Cash Flow | - | -89.94M | 18.68M | 20.77M | -20.59M |
| Financing Cash Flow | - | 96.91M | 5.30M | 25.00K | 45.77M |
| Capital Expenditure | - | -904.00K | -6.40M | -2.24M | -6.08M |
| Free Cash Flow | - | -24.78M | -24.36M | -22.02M | -32.76M |
| Net Change in Cash | - | -16.91M | 6.02M | 1.01M | -1.50M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | -32.0% | -34.5% | -50.7% | -55.3% |
| ROCE % | - | -27.7% | -35.6% | -46.5% | -44.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Gem Investment Advisors, LLC | 2.07% | 1.43M | $21.86M |
| 2 | HighTower Advisors, LLC | 1.26% | 874.99K | $13.33M |
| 3 | Boothbay Fund Management, LLC | 1.12% | 773.48K | $11.79M |
| 4 | Aquamarine Financial (cayman) Ltd | 1.04% | 721.50K | $11.00M |
| 5 | Pier Capital, LLC | 1.00% | 691.94K | $10.55M |
| 6 | UBS Group AG | 0.93% | 642.26K | $9.79M |
| 7 | Apella Capital, LLC | 0.55% | 382.28K | $5.83M |
| 8 | ARK Investment Management, LLC | 0.40% | 277.09K | $4.22M |
| 9 | Polen Capital Management, LLC | 0.32% | 220.75K | $3.36M |
| 10 | Focus Partners Wealth | 0.27% | 184.73K | $2.82M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DRTS
This Small-Cap Biotech Posted Impressive Brain Cancer Data – But There’s A Catch - Stocktwits
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxQWF83MVBVbTVid3hZRkNvOTB1Nk82UzE1SEc1ejV1ZkRqS1hMeXJ4NnlCN2NQaFh6bnJ3RGcydHpoVXlEa3pxT0ktdURKREE1TXBOLTJKY2RsNWtHZmVmcG5UWFZvYkZMVGJzOGRCT291cjBMaWtCMmlhSkxNT0U1VXpHd01pVGN1U1pnRH…
Is Trial Enrollment Completion Altering The Investment Case For Alpha Tau Medical (DRTS)? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxQRVdQSHhUZ3Q2dFd4Z2drWVV6NC12T3Izd0NGaXVHeV9maXYyeVhxajhlNWp5M1ZNd044MjdIM1R5WGp6ZURrakU4Z1dvUWxGTHRxOE9zbXlrZjRhUVhyWUdmSnV3Smt1VkNnWUd2YjdLNVloX0luVzhIVXhod2ZEd24wNXo3S3VRcWc1Un…
DRTS Stock Price and Chart — TASE:DRTS - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiWkFVX3lxTE11T0V4TUVTWXpzdFd3enVsMG14WnNLaF81VG5NVFE0YUQ5dGtaMGN3dG5kTmNIZXRrVW43dG1SRXRzLV9URGNicDZGVVA4cU4zWXQ0VzlRM09tZw?oc=5" target="_blank">DRTS Stock Price and Chart — TASE:DRTS</a>&nb…
(DRTS) Volatility Zones as Tactical Triggers - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxNdTJ0bU9HNUFDOGxxaXFFWE5LdWEzUDFId3hsMTQ5NElZR1R2SDlLUzlFRjdJYmVpekp6bTQyTDduZ0tTUXk2RWx1Rl9VTW9iWWFfWVRCT21obklpbGhJa2Nza1c3VFZMVGhBbzJWSGlIR21NN2NySWZPckhnU2pnS2dVeFlrcG9fajRYRE…
DRTS Stock Shot Up A Whopping 22% Today – Why A $196.5M Prostate Cancer Deal Got Investors Buzzing - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxOOXNKMGZveHYyeTFrc0k5Q21LdGgyellnZDdnZTF6LW5zRF9fU1JYeDZzU1oyMXljdFpWN1NnM2hDY1RPNzczMEZYTWZFVHV1OGlIRVlHS3RmSElCUkxsMkJoXzQ0Z2VLa3Bna2R4Um52ZXltRnJla1NsUE0tNVJfS3V6WmdzQ3ZldXNLUF…
Alpha Tau’s pancreatic cancer study grows from 12 to 48 patients as enrollment closes - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxOLVVCSmZ0VnJEbThJYnNZX1lMX093SEJ5bnRreFNIYi1nNlFSS2ljMnB5ZXA1TEJiX1ZGRXk1Z1VlNUQ0YWRPWS1uWmU0Y2ZkUTFHRDd0X25VU0tBVXRlT192YWxwRWpHSFd4LUx6RHRDVEZBNGhxRFlUaDBQR1hOOFA2NEdFeDhSQWQxdl…
DRTS — Frequently Asked Questions
What is the current share price of Alpha Tau Medical Ltd. (DRTS)?
As of 2026-09-19 21:16 PDT, Alpha Tau Medical Ltd. (DRTS) trades at $14.84 on NasdaqCM. Its 52-week range is $3.06 to $15.03.
What is the market capitalisation of DRTS?
Alpha Tau Medical Ltd. (DRTS) has a market capitalisation of $1.37B on NasdaqCM.
What is the P/E ratio of DRTS?
DRTS trades at a trailing price-to-earnings (P/E) ratio of -14.27. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 29.92.
What is the return on equity (ROE) of DRTS?
DRTS has a return on equity (ROE) of -141.68%. Its return on capital employed (ROCE) is -44.45%.
Is DRTS a good stock to buy?
This page provides a data-driven analysis of Alpha Tau Medical Ltd. (DRTS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.